Anti-DR5/TRAILR2/TNFRSF10B Rabbit Polyclonal Antibody for WB and ELISA - O14763

Core Product Specifications and Parameters

Biological Background: DR5/TRAILR2/TNFRSF10B Function and Localization

• DR5/TRAILR2/TNFRSF10B is a member of the tumor necrosis factor receptor superfamily, also known as death receptor 5 (DR5), KILLER, and TRAIL-R2. It is encoded by the TNFRSF10B gene on chromosome 8p21.3.
• The receptor binds to the cytotoxic ligand TNFSF10/TRAIL, triggering apoptosis through recruitment of the adaptor FADD and caspase-8 to form the death-inducing signaling complex (DISC). Related references: PMID:10549288
• Following DISC formation, caspase-8 is proteolytically activated, initiating a cascade of caspases that execute apoptosis. DR5-mediated signaling also activates NF-kB, linking it to survival pathways.
• DR5 is essential for ER stress-induced apoptosis, highlighting its role in cellular stress responses.
• The protein is a type I transmembrane glycoprotein located at the plasma membrane. It contains characteristic extracellular cysteine-rich domains and a cytoplasmic death domain.
• DR5 is widely expressed in adult and fetal tissues, with particularly high expression in tumor cell lines (e.g., HeLa, K-562, HL-60, SW480, A-549, G-361) and in heart, liver, pancreas, spleen, thymus, prostate, ovary, uterus, placenta, and intestinal tract; it is not detectable in brain.
• Alternative splicing generates multiple isoforms, and the protein undergoes post-translational modifications including glycosylation and disulfide bond formation, which are critical for receptor stability and ligand binding.

Experimental Guidance and Technical Tips

• The immunogen used for this polyclonal antibody corresponds to amino acids 260-440 of human DR5/TRAILR2/TNFRSF10B, which encompasses the intracellular death domain and part of the cytoplasmic region. This design may be suitable for detecting both full-length and cleaved receptor forms.
• Given the specificity for human DR5, experimenters should validate cross-reactivity if using non-human samples; the product is confirmed for human reactivity.
• For Western blot (WB), cell lines with high DR5 expression (e.g., HeLa, K-562, SW480) can serve as positive controls, while brain tissues may be negative. Consider using appropriate lysis and reducing conditions to observe the ~48 kDa band.
• ELISA applications may require optimization of coating conditions and detection system due to the receptor's membrane localization; recombinant DR5 protein or cell lysates can be explored as capture targets.
• Since DR5 undergoes alternative splicing and glycosylation, multiple bands or a smear may be observed in some samples. Using deglycosylation enzymes or confirming with siRNA knockdown can help validate band identity.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic. This anti-DR5/TRAILR2 polyclonal antibody is part of our extensive portfolio for apoptosis and cancer research, supporting IVD development with validated antibody pairs, optimized monoclonal/polyclonal antibodies, bulk ancillary reagents, and rare target raw-material sourcing.